SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Deep Vein Thrombosis
Conditions
Deep Vein Thrombosis
Trial Timeline
May 1, 2003 → Sep 1, 2005
NCT ID
NCT00067093About SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA) is a phase 3 stage product being developed by Sanofi for Deep Vein Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00067093. Target conditions include Deep Vein Thrombosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00067093 | Phase 3 | Completed |
Competing Products
20 competing products in Deep Vein Thrombosis